81669-57-0

Basic information

• Product Name: Anistreplasa [INN-Spanish]
• Synonyms: Anistreplasa [INN-Spanish];Anistreplase;APSAC;BRL 26921;Eminase
• CAS NO: 81669-57-0
• Molecular Weight: 0
• Mol File: 81669-57-0.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Anistreplasa [INN-Spanish](CAS DataBase Reference)
• NIST Chemistry Reference: Anistreplasa [INN-Spanish](81669-57-0)
• EPA Substance Registry System: Anistreplasa [INN-Spanish](81669-57-0)

Safety Data

• Hazardous Substances Data: 81669-57-0(Hazardous Substances Data)

Usage

Description

Anistreplasa [INN-Spanish], also known as APSAC, is an anisoylated human plasminogen-streptokinase complex that serves as a thrombolytic agent. It is primarily used in the treatment of myocardial infarction, offering several advantages over other thrombolytics such as a longer half-life, ease of administration, and a more specific local antithrombotic effect.
Brand Name: Eminase

Uses

Used in Pharmaceutical Industry:
Anistreplasa [INN-Spanish] is used as a thrombolytic agent for the treatment of myocardial infarction. It is effective in breaking down blood clots, improving blood flow, and reducing the damage caused by the blocked artery. Its longer half-life, ease of administration, and more specific local antithrombotic effect make it a preferred choice over other thrombolytics like alteplase and streptokinase.

Manufacturing Process

Preparation of freeze dried p-anisoyl streptokinase/plasminogen complex without internal peptide bond cleavages: Streptokinase (250,000 units, Kabi, Stockholm, Sweden) was dissolved in 0.1 M trishydroxymethylmethane hydrochloride pH 7.4 (2.5 ml) and a solution of 0.1 M p-amidinophenyl p'-anisate in dimethylsulphoxide (0.25 ml) added. A slight cloudiness resulted. To this mixture was added 0.5 ml of a solution of human lys-plasminogen (8.99 mg/ml in the above buffer) [Kabi, Stockholm] and the solution was thoroughly and rapidly mixed. After standing on ice for 15 minutes, the solution was stored on ice until use. After approximaely 2 hours 0.4 ml (40,000 units) of the material was diluted with 3.0 ml of a slurry of L-lysine-sepharose 4B (a 33% wet wt/volume suspension in the above buffer) and stood at 0°C for 1 hour. The gel was filtered on a glass sinter funnel at 4°C under suction and washed with the buffer (100 ml). The gel was eluted under gentle suction with the same buffer containing 0.1 M ε- aminocaproic acid (3 lots of 5 ml). The combined filtrates were dialysed for 2 hours at 4°C against ammonium bicarbonate buffer (50 mM pH 7.0) containing 2.5% w/v mannitol. The product was then freeze dried to 0.799 g of a white solid. Approximately 195 mg of this material was analysed by slab gel polyacrylamide gel electrophoresis using 10% w/v gels in the presence of sodium dodecyl sulphate. Two main polypeptide bands were observed corresponding to lys-plasminogen (m.w. 84,000) and streptokinase (m.w. 47,000). There was also a trace of contaminating human serum albumin derived from the commercial streptokinase preparation.

Therapeutic Function

Thrombolytic